Zacks Investment Research upgraded shares of Arrowhead Research (ARWR) from N/A to OUTPERFORM on June 24, 2013, with a target price of $5.00.
ARWR is a clinical stage biotech company focused on RNAi and small molecule targeted therapy using three proprietary platform technologies. ARWR has built a diversified pipeline targeting a variety of indications ranging from infections to cancers and to obesity. We are optimistic about the Company's HBV program ARC-520, which will enter into Phase I in 2H13. Two other lead candidates Adipotide (obesity) and CALAA-01 (cancer) are also in Phase I trials. Balance sheet has been boosted by recent financing. We are optimistic about the prospect of ARWR. Valuation is attractive at this time based on strong fundamentals.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on Arrowhead Research (ARWR),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment